FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3175002612> ?p ?o ?g. }

• W3175002612 abstract "Introduction: Pulmonary toxicity can be a lethal side effect associated with many newer anti-cancer agents especially immune checkpoint inhibitors. In the times of ever-growing patient population on precision oncology therapies, timely identification of drug induced lung injury can be challenging. Here we highlight pulmonary toxicity as an adverse effect of brentuximab vedotin (BV). Case Report: A 70-year-old male, former smoker with a recent diagnosis of advanced stage classic Hodgkin's lymphoma recently started on BV, presented with two days of progressive dyspnea, fever and productive cough. He denied exposure to sick contacts and recent travel. Of note, he was hospitalized ten days earlier for suspected pneumonia and had completed a course of antibiotics. Vital signs were notable for temperature 101.7°F, heart rate 110 beats/minute, respiratory rate 30 breaths/minute and oxygen saturation of 90% on 6L of oxygen. Physical examination was noteworthy for bibasilar rhonchi. Lab workup was unremarkable and COVID-19 test was negative. Imaging studies displayed new bilateral basal infiltrates on CXR and CT scan of the chest demonstrated new alveolar opacities involving the lower lobes, and interval improvement was noted in the upper lobe opacities. He was treated for presumed pneumonia with broad spectrum antibiotics. However, his oxygen requirements continued to increase, necessitating a further infectious and rheumatologic workup which was negative. After thorough diagnostic evaluation, in the absence of other plausible etiology, the patient's symptoms were attributed to pneumonitis secondary to the chemotherapeutic agent BV. Henceforth, intravenous steroids were initiated which resulted in clinical improvement. Further treatment with BV was withheld and he was discharged on a steroid taper. One month later, a subsequent CT scan of the chest demonstrated complete resolution of bilateral alveolar opacities. Discussion: BV is a CD30 directed antibody-drug conjugate used in advanced or refractory classic Hodgkin's lymphoma. It is known to cause a higher rate of pulmonary toxicity when combined with bleomycin containing regimens with a reported incidence of 40%, hence this combination is contraindicated. However, the incidence of pneumonitis is noted to be only 5% in patients receiving BV in combination with non-bleomycin regimens, which was the case in our patient in lieu of his two back-to-back hospitalizations after receiving two cycles of BV. The exact mechanism of action is unclear but is probably due to hypersensitivity pneumonitis. Although it is a diagnosis of exclusion, a high degree of suspicion is crucial for prompt cessation of the drug in order to prevent adverse outcomes." @default.
• W3175002612 created "2021-07-05" @default.
• W3175002612 creator A5044618948 @default.
• W3175002612 creator A5049851009 @default.
• W3175002612 creator A5073982446 @default.
• W3175002612 date "2021-05-01" @default.
• W3175002612 modified "2023-09-25" @default.
• W3175002612 title "Deceptive Lungs: Is it Brentuximab Induced Pneumonitis or Pneumonia" @default.
• W3175002612 doi "https://doi.org/10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a2123" @default.
• W3175002612 hasPublicationYear "2021" @default.
• W3175002612 type Work @default.
• W3175002612 sameAs 3175002612 @default.
• W3175002612 citedByCount "1" @default.
• W3175002612 countsByYear W31750026122021 @default.
• W3175002612 crossrefType "proceedings-article" @default.
• W3175002612 hasAuthorship W3175002612A5044618948 @default.
• W3175002612 hasAuthorship W3175002612A5049851009 @default.
• W3175002612 hasAuthorship W3175002612A5073982446 @default.
• W3175002612 hasBestOaLocation W31750026121 @default.
• W3175002612 hasConcept C126322002 @default.
• W3175002612 hasConcept C142724271 @default.
• W3175002612 hasConcept C177713679 @default.
• W3175002612 hasConcept C2777134676 @default.
• W3175002612 hasConcept C2777714996 @default.
• W3175002612 hasConcept C2777914695 @default.
• W3175002612 hasConcept C2778191690 @default.
• W3175002612 hasConcept C2779338263 @default.
• W3175002612 hasConcept C2779524853 @default.
• W3175002612 hasConcept C2992779791 @default.
• W3175002612 hasConcept C71924100 @default.
• W3175002612 hasConceptScore W3175002612C126322002 @default.
• W3175002612 hasConceptScore W3175002612C142724271 @default.
• W3175002612 hasConceptScore W3175002612C177713679 @default.
• W3175002612 hasConceptScore W3175002612C2777134676 @default.
• W3175002612 hasConceptScore W3175002612C2777714996 @default.
• W3175002612 hasConceptScore W3175002612C2777914695 @default.
• W3175002612 hasConceptScore W3175002612C2778191690 @default.
• W3175002612 hasConceptScore W3175002612C2779338263 @default.
• W3175002612 hasConceptScore W3175002612C2779524853 @default.
• W3175002612 hasConceptScore W3175002612C2992779791 @default.
• W3175002612 hasConceptScore W3175002612C71924100 @default.
• W3175002612 hasLocation W31750026121 @default.
• W3175002612 hasOpenAccess W3175002612 @default.
• W3175002612 hasPrimaryLocation W31750026121 @default.
• W3175002612 hasRelatedWork W1867178123 @default.
• W3175002612 hasRelatedWork W1961847619 @default.
• W3175002612 hasRelatedWork W1978741949 @default.
• W3175002612 hasRelatedWork W1984512844 @default.
• W3175002612 hasRelatedWork W1994362420 @default.
• W3175002612 hasRelatedWork W2073723626 @default.
• W3175002612 hasRelatedWork W2273571079 @default.
• W3175002612 hasRelatedWork W2428394429 @default.
• W3175002612 hasRelatedWork W4250658270 @default.
• W3175002612 hasRelatedWork W127139171 @default.
• W3175002612 isParatext "false" @default.
• W3175002612 isRetracted "false" @default.
• W3175002612 magId "3175002612" @default.
• W3175002612 workType "article" @default.